ARTICLE
22 November 2018

European Data Protection Board Issues Statement About Work Underway But Nothing Of Real Substance Yet

SS
Seyfarth Shaw LLP

Contributor

With more than 900 lawyers across 18 offices, Seyfarth Shaw LLP provides advisory, litigation, and transactional legal services to clients worldwide. Our high-caliber legal representation and advanced delivery capabilities allow us to take on our clients’ unique challenges and opportunities-no matter the scale or complexity. Whether navigating complex litigation, negotiating transformational deals, or advising on cross-border projects, our attorneys achieve exceptional legal outcomes. Our drive for excellence leads us to seek out better ways to work with our clients and each other. We have been first-to-market on many legal service delivery innovations-and we continue to break new ground with our clients every day. This long history of excellence and innovation has created a culture with a sense of purpose and belonging for all. In turn, our culture drives our commitment to the growth of our clients, the diversity of our people, and the resilience of our workforce.
The statement covered a range of topics being discussed by the Board, but no substantive publications.
Worldwide Privacy

The European Data Protection Board (EDPB) recently issued a report after their November 16, 2018 plenary session. The statement covered a range of topics being discussed by the Board, but no substantive publications. The EDPB is charged with ensuring that GDPR is applied consistently across the EU and that there is consistent enforcement by DPAs across the Union. The Board is also tasked with issuing guidelines on the interpretation the GDPR (formerly the charge of the Article 29 Working Party), and making binding decisions about cross-border disputes. The Board is made up of the head DPA or representatives from each member country.

An EU-Japan adequacy finding appears to be extremely close, and the Board announced they are at work on guidelines about the intersection between Clinical Trials Regulation and the GDPR for medical device and pharmaceutical companies. There have now been four "plenary meetings" of the EDPB. Some may consider no action on the part of the Board a good thing, but there are some significant concepts which eventually need clarification, including a formal process and procedure on appeals of DPA enforcement and fines, and modernization of the outdated Model Contractual Clauses, among other things. The essential message from the EDPB continues to be "stay tuned," and seems likely that no real substantive publications will come through until early 2019.

The complete press release from the EDPB can be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More